A carregar...
Orally administered anti-eotaxin-1 monoclonal antibody is biologically active in the gut and alleviates immune-mediated hepatitis: A novel anti-inflammatory personalized therapeutic approach
Personalized therapies are designed to optimize the safety-to-efficacy ratio by selecting patients with higher response rates based on specific biomarkers. Inflammation plays a vital role in the pathogenesis of non-alcoholic steatohepatitis (NASH), a common liver disorder. Eotaxin-1 plays a role in...
Na minha lista:
| Publicado no: | Int J Immunopathol Pharmacol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8287423/ https://ncbi.nlm.nih.gov/pubmed/34275345 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/20587384211021215 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|